Position in LYEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$4,833,551
+$3,246,866 QoQ
Shares Held
344,025
+334.9% QoQ
Ownership
1.40%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
#10
of 87 holders
Holding Since
Mar 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Opaleye Management Inc. holds $678,840,611 across 50 Biotechnology names. LYEL ranks #31 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IRON |
Disc Medicine, Inc.
|
855,000 | $62,534,700 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
1,439,996 | $52,991,852 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
390,000 | $51,764,700 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
3,550,000 | $47,960,500 | |
| 5 | SLGL |
Sol-Gel Technologies Ltd.
|
500,000 | $37,070,000 | |
| 6 | RZLT |
Rezolute, Inc.
|
6,300,000 | $32,760,000 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
535,000 | $29,392,900 | |
| 8 | IMMX |
Immix Biopharma, Inc.
|
2,345,000 | $24,176,950 |
All Filings in LYEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,833,551 | 344,025 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,586,685 | 79,097 | Shares | Sole | 2026-05-15 | |
| 2024-09-30 | $1,925,100 | 1,395,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,421,500 | 1,670,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $7,481,650 | 3,355,000 | Shares | Sole | 2024-05-29 | |
| No filing history on record for this holder in this stock. | ||||||